Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Foralumab - Tiziana Life Sciences

Drug Profile

Foralumab - Tiziana Life Sciences

Alternative Names: NI-0401; NI-0401/α-CD3; TZLS-401

Latest Information Update: 08 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex; NovImmune SA
  • Developer Harvard Medical School; Light Chain Bioscience; NovImmune SA; Tiziana Life Sciences
  • Class Anti-inflammatories; Hepatoprotectants; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Crohn's disease
  • Phase I Multiple sclerosis; Primary biliary cirrhosis
  • Preclinical Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Discontinued Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 30 Sep 2019 Tiziana Life Sciences completes a phase I trial in Multiple sclerosis (In volunteers) in USA (Intranasal)
  • 17 Sep 2019 The US FDA approves application for the initiation of a phase I clinical trial of oral enteric-coated capsule formulation of Foralumab in healthy volunteers in USA
  • 17 Sep 2019 Tiziana Life Sciences plans a phase I trial in Healthy volunteers in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top